AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
OLE Study to Evaluate Safety / Efficacy of ZD4522
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3500
- Registration Number
- NCT00654303
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Heart Disease
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00653588
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDyslipidaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00653744
Symbicort in Asthmatic Children - SEEDLING
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 405
- Registration Number
- NCT00651547
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterolDrug: budesonide and placebo
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00652392
Titratable Dosing in Moderate to Severe Asthmatics
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterolDrug: Symbicort pMDI + budesonide HFA pMDI
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 570
- Registration Number
- NCT00651768
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00652002
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00651651
Symbicort Onset of Action 1
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: fluticasone/salmeterol (Advair Diskus)Drug: albuterol (Ventolin)Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00646620
Long-Term Safety of Symbicort in Asthmatic Children - SAPLING
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)Drug: budesonide (Pulmicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT00646529
© Copyright 2025. All Rights Reserved by MedPath